Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperbaric Oxygenation | 1 | 2019 | 6 | 0.600 |
Why?
|
| Atlanto-Occipital Joint | 1 | 2019 | 4 | 0.590 |
Why?
|
| Osteoradionecrosis | 1 | 2019 | 5 | 0.590 |
Why?
|
| Cervical Vertebrae | 2 | 2019 | 54 | 0.590 |
Why?
|
| Obesity, Morbid | 1 | 2019 | 75 | 0.570 |
Why?
|
| Spinal Fusion | 1 | 2019 | 64 | 0.560 |
Why?
|
| Vertebral Artery | 1 | 2017 | 7 | 0.520 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2017 | 38 | 0.510 |
Why?
|
| Wounds, Gunshot | 1 | 2017 | 35 | 0.500 |
Why?
|
| Neurosurgical Procedures | 5 | 2017 | 101 | 0.420 |
Why?
|
| Coma | 1 | 2013 | 2 | 0.390 |
Why?
|
| Multicenter Studies as Topic | 2 | 2015 | 120 | 0.390 |
Why?
|
| Electroencephalography | 1 | 2013 | 76 | 0.380 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2012 | 21 | 0.370 |
Why?
|
| Arteriovenous Fistula | 1 | 2012 | 19 | 0.370 |
Why?
|
| Analgesics | 2 | 2016 | 117 | 0.360 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2015 | 565 | 0.330 |
Why?
|
| Healthcare Common Procedure Coding System | 1 | 2010 | 1 | 0.330 |
Why?
|
| Relative Value Scales | 1 | 2010 | 2 | 0.330 |
Why?
|
| Reimbursement Mechanisms | 1 | 2010 | 13 | 0.320 |
Why?
|
| Humans | 28 | 2020 | 34474 | 0.300 |
Why?
|
| Paraplegia | 1 | 2009 | 7 | 0.300 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2009 | 8 | 0.300 |
Why?
|
| Spinal Cord Compression | 1 | 2009 | 7 | 0.300 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2009 | 7 | 0.300 |
Why?
|
| Pain, Postoperative | 2 | 2012 | 205 | 0.300 |
Why?
|
| Diskectomy | 1 | 2009 | 18 | 0.300 |
Why?
|
| Spinal Nerves | 1 | 2009 | 72 | 0.290 |
Why?
|
| Neurosurgery | 3 | 2017 | 38 | 0.280 |
Why?
|
| Phantom Limb | 1 | 2007 | 4 | 0.260 |
Why?
|
| Pain | 2 | 2010 | 330 | 0.260 |
Why?
|
| Postoperative Complications | 2 | 2010 | 849 | 0.260 |
Why?
|
| Ketamine | 1 | 2007 | 20 | 0.260 |
Why?
|
| Amputation | 1 | 2007 | 44 | 0.260 |
Why?
|
| Radiosurgery | 1 | 2010 | 360 | 0.250 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2005 | 29 | 0.230 |
Why?
|
| Spinal Cord | 2 | 2008 | 150 | 0.230 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2005 | 39 | 0.230 |
Why?
|
| Pain Threshold | 1 | 2005 | 105 | 0.230 |
Why?
|
| Dura Mater | 2 | 2017 | 14 | 0.230 |
Why?
|
| Treatment Outcome | 6 | 2019 | 3618 | 0.220 |
Why?
|
| Stroke | 3 | 2015 | 700 | 0.210 |
Why?
|
| Cooperative Behavior | 2 | 2017 | 87 | 0.200 |
Why?
|
| Adult | 8 | 2019 | 10015 | 0.200 |
Why?
|
| Male | 13 | 2019 | 20697 | 0.190 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2002 | 6 | 0.180 |
Why?
|
| Laminectomy | 1 | 2002 | 17 | 0.180 |
Why?
|
| Middle Aged | 12 | 2019 | 12703 | 0.180 |
Why?
|
| Spine | 1 | 2002 | 45 | 0.180 |
Why?
|
| Hypotension | 1 | 2002 | 49 | 0.180 |
Why?
|
| Intraoperative Complications | 1 | 2002 | 62 | 0.180 |
Why?
|
| Meningeal Neoplasms | 2 | 2020 | 49 | 0.170 |
Why?
|
| Meningioma | 2 | 2020 | 59 | 0.170 |
Why?
|
| Orbital Neoplasms | 1 | 2020 | 1 | 0.160 |
Why?
|
| Analgesia, Epidural | 2 | 2012 | 55 | 0.150 |
Why?
|
| Gastric Bypass | 1 | 2019 | 31 | 0.150 |
Why?
|
| Needs Assessment | 1 | 2019 | 81 | 0.150 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 230 | 0.140 |
Why?
|
| Reoperation | 1 | 2019 | 265 | 0.140 |
Why?
|
| Brain Neoplasms | 3 | 2013 | 649 | 0.140 |
Why?
|
| United States | 7 | 2017 | 4267 | 0.140 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2020 | 202 | 0.140 |
Why?
|
| Analysis of Variance | 3 | 2012 | 508 | 0.130 |
Why?
|
| Pain Measurement | 3 | 2012 | 385 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2017 | 1386 | 0.130 |
Why?
|
| Tissue Adhesives | 1 | 2017 | 7 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 589 | 0.130 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2017 | 7 | 0.130 |
Why?
|
| Occult Blood | 2 | 2007 | 11 | 0.120 |
Why?
|
| Female | 14 | 2017 | 21490 | 0.120 |
Why?
|
| Periodicals as Topic | 1 | 2017 | 91 | 0.120 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2016 | 21 | 0.120 |
Why?
|
| Pelvic Pain | 1 | 2016 | 23 | 0.120 |
Why?
|
| Amines | 1 | 2016 | 24 | 0.120 |
Why?
|
| Hydrogels | 1 | 2017 | 127 | 0.120 |
Why?
|
| Intracranial Aneurysm | 1 | 2017 | 68 | 0.120 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2016 | 83 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2017 | 186 | 0.120 |
Why?
|
| Time Factors | 4 | 2012 | 2352 | 0.110 |
Why?
|
| Therapeutic Equipoise | 1 | 2015 | 1 | 0.110 |
Why?
|
| Physicians | 1 | 2017 | 167 | 0.110 |
Why?
|
| Aged | 9 | 2017 | 10998 | 0.110 |
Why?
|
| Primary Prevention | 1 | 2014 | 57 | 0.110 |
Why?
|
| Thrombolytic Therapy | 2 | 2015 | 67 | 0.110 |
Why?
|
| Colorectal Neoplasms | 2 | 2007 | 229 | 0.100 |
Why?
|
| Receptors, Somatostatin | 1 | 2013 | 5 | 0.100 |
Why?
|
| Hemangiopericytoma | 1 | 2013 | 6 | 0.100 |
Why?
|
| Adolescent | 2 | 2019 | 3799 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2019 | 1506 | 0.100 |
Why?
|
| Embolization, Therapeutic | 2 | 2017 | 86 | 0.100 |
Why?
|
| Ischemic Attack, Transient | 1 | 2014 | 57 | 0.100 |
Why?
|
| Aneurysm, Ruptured | 2 | 2017 | 33 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 2366 | 0.100 |
Why?
|
| Quadriplegia | 1 | 2013 | 12 | 0.100 |
Why?
|
| Status Epilepticus | 1 | 2013 | 21 | 0.100 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2012 | 38 | 0.090 |
Why?
|
| Hypertension | 1 | 2019 | 1024 | 0.090 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2012 | 22 | 0.090 |
Why?
|
| Craniocerebral Trauma | 1 | 2012 | 58 | 0.090 |
Why?
|
| Disease Progression | 3 | 2010 | 633 | 0.090 |
Why?
|
| Hepatectomy | 1 | 2012 | 57 | 0.090 |
Why?
|
| Anesthetics, Local | 1 | 2012 | 96 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 429 | 0.080 |
Why?
|
| Central Cord Syndrome | 1 | 2010 | 2 | 0.080 |
Why?
|
| Point Mutation | 1 | 2010 | 30 | 0.080 |
Why?
|
| Superoxide Dismutase | 1 | 2010 | 48 | 0.080 |
Why?
|
| Neuroradiography | 1 | 2010 | 2 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2009 | 540 | 0.080 |
Why?
|
| Cerebral Infarction | 1 | 2010 | 25 | 0.080 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 20 | 0.080 |
Why?
|
| Angioplasty | 1 | 2010 | 31 | 0.080 |
Why?
|
| Radiation Oncology | 1 | 2010 | 14 | 0.080 |
Why?
|
| Spinal Neoplasms | 1 | 2010 | 23 | 0.080 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 60 | 0.080 |
Why?
|
| Young Adult | 5 | 2017 | 2825 | 0.080 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2010 | 71 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 819 | 0.080 |
Why?
|
| Analgesics, Opioid | 1 | 2012 | 265 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2010 | 130 | 0.080 |
Why?
|
| Spinal Cord Diseases | 1 | 2009 | 14 | 0.080 |
Why?
|
| Sarcoidosis | 1 | 2009 | 33 | 0.070 |
Why?
|
| Angiography | 1 | 2009 | 79 | 0.070 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2008 | 8 | 0.070 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 193 | 0.070 |
Why?
|
| Vasospasm, Intracranial | 1 | 2008 | 13 | 0.070 |
Why?
|
| Prognosis | 1 | 2013 | 1603 | 0.070 |
Why?
|
| Lumbar Vertebrae | 1 | 2009 | 113 | 0.070 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2008 | 25 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2020 | 3812 | 0.070 |
Why?
|
| Brain | 2 | 2013 | 1031 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2010 | 260 | 0.070 |
Why?
|
| Mass Screening | 2 | 2007 | 268 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2010 | 349 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2007 | 33 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2010 | 330 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2007 | 597 | 0.060 |
Why?
|
| Trauma, Nervous System | 1 | 2005 | 9 | 0.060 |
Why?
|
| Rats, Wistar | 1 | 2005 | 113 | 0.060 |
Why?
|
| Functional Laterality | 1 | 2005 | 66 | 0.060 |
Why?
|
| Reaction Time | 1 | 2005 | 131 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2017 | 583 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2005 | 328 | 0.050 |
Why?
|
| Palaemonidae | 1 | 2004 | 1 | 0.050 |
Why?
|
| American Heart Association | 2 | 2014 | 92 | 0.050 |
Why?
|
| Phylogeny | 1 | 2004 | 68 | 0.050 |
Why?
|
| Behavior, Animal | 1 | 2005 | 303 | 0.050 |
Why?
|
| Orbit | 2 | 2020 | 19 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 526 | 0.050 |
Why?
|
| Craniofacial Dysostosis | 1 | 2002 | 6 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2004 | 254 | 0.050 |
Why?
|
| Intracranial Hypertension | 1 | 2002 | 21 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2002 | 42 | 0.050 |
Why?
|
| Craniosynostoses | 1 | 2002 | 62 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2012 | 87 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 1118 | 0.040 |
Why?
|
| Rats | 1 | 2005 | 1946 | 0.040 |
Why?
|
| Sphenoid Bone | 1 | 2020 | 3 | 0.040 |
Why?
|
| Length of Stay | 2 | 2012 | 335 | 0.040 |
Why?
|
| Titanium | 1 | 2020 | 11 | 0.040 |
Why?
|
| Surgical Mesh | 1 | 2020 | 50 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2016 | 2461 | 0.040 |
Why?
|
| International Cooperation | 1 | 2017 | 33 | 0.030 |
Why?
|
| China | 1 | 2017 | 58 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 69 | 0.030 |
Why?
|
| Valsalva Maneuver | 1 | 2017 | 3 | 0.030 |
Why?
|
| Base Sequence | 2 | 2010 | 264 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 399 | 0.030 |
Why?
|
| Publishing | 1 | 2017 | 66 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 323 | 0.030 |
Why?
|
| Colonoscopy | 2 | 2007 | 45 | 0.030 |
Why?
|
| Animals | 2 | 2005 | 8544 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 197 | 0.030 |
Why?
|
| Netherlands | 1 | 2015 | 25 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2016 | 193 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2015 | 71 | 0.030 |
Why?
|
| Obesity | 1 | 2002 | 1244 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2012 | 4150 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2014 | 168 | 0.020 |
Why?
|
| Skull Base Neoplasms | 1 | 2012 | 4 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 231 | 0.020 |
Why?
|
| Scotland | 1 | 2012 | 1 | 0.020 |
Why?
|
| Scalp | 1 | 2012 | 38 | 0.020 |
Why?
|
| Skull | 1 | 2012 | 49 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 304 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 168 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2012 | 214 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 71 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2008 | 984 | 0.020 |
Why?
|
| Syndrome | 1 | 2010 | 76 | 0.020 |
Why?
|
| Specialty Boards | 1 | 2010 | 11 | 0.020 |
Why?
|
| Certification | 1 | 2010 | 30 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 58 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 389 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 75 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2010 | 123 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2010 | 251 | 0.020 |
Why?
|
| Curriculum | 1 | 2010 | 217 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 2008 | 60 | 0.020 |
Why?
|
| Adenomatous Polyps | 1 | 2007 | 8 | 0.020 |
Why?
|
| Risk Factors | 1 | 2014 | 4136 | 0.020 |
Why?
|
| Guaiac | 1 | 2006 | 1 | 0.020 |
Why?
|
| Immunologic Tests | 1 | 2006 | 4 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2006 | 15 | 0.010 |
Why?
|
| Patient Participation | 1 | 2007 | 93 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 612 | 0.010 |
Why?
|
| Fresh Water | 1 | 2004 | 3 | 0.010 |
Why?
|
| DNA, Ribosomal | 1 | 2004 | 3 | 0.010 |
Why?
|
| Base Pairing | 1 | 2004 | 6 | 0.010 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2004 | 20 | 0.010 |
Why?
|
| Geography | 1 | 2004 | 36 | 0.010 |
Why?
|
| DNA, Mitochondrial | 1 | 2004 | 34 | 0.010 |
Why?
|
| Frontal Bone | 1 | 2002 | 14 | 0.010 |
Why?
|
| Forehead | 1 | 2002 | 13 | 0.010 |
Why?
|
| Parietal Bone | 1 | 2002 | 13 | 0.010 |
Why?
|
| Papilledema | 1 | 2002 | 13 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 235 | 0.010 |
Why?
|
| Decompression, Surgical | 1 | 2002 | 57 | 0.010 |
Why?
|
| Recurrence | 1 | 2002 | 295 | 0.010 |
Why?
|
| Infant | 1 | 2002 | 1122 | 0.010 |
Why?
|